ORGANIZATION, PRINCIPAL ACTIVITIES

3 Months Ended

Jun. 30, 2017

Disclosure Text Block [Abstract]

ORGANIZATION, PRINCIPAL ACTIVITIES

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

Nemaura Medical Inc. ("Nemaura" or the "Company"), through its operating subsidiaries, performs medical device research of a continuous glucose monitoring system ("CGM"), named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using unique sensors and interpreted using a unique algorithm.

Nemaura is a Nevada holding company organized in 2013. Nemaura owns one hundred percent (100%) of Region Green Limited, a British Virgin Islands corporation formed ("RGL") on December 12, 2013.  Region Green Limited owns one hundred percent (100%) of the stock in Dermal Diagnostic (Holdings) Limited, an England and Wales corporation ("DDHL") formed on December 11, 2013, which in turn owns one hundred percent (100%) of Dermal Diagnostics Limited, an England and Wales corporation formed on January 20, 2009 ("DDL"), and one hundred percent (100%) of Trial Clinic Limited, an England and Wales corporation formed on January 12, 2011 ("TCL").

DDL is a diagnostic medical device company headquartered in Loughborough, Leicestershire, England, and is engaged in the discovery, development and commercialization of diagnostic medical devices. The Company's initial focus has been on the development of the sugarBEAT device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source, which is designed to enable trending or tracking of blood glucose levels. Except for a US cash account (approximately $48,000 at June 30, 2017), all of the Company’s operations and assets are located in England.

The following diagram illustrates our corporate and shareholder structure as of June 30, 2017:

	Nemaura Medical Inc. Nevada Corporation
	Region Green Limited British Virgin Islands Corporation
	Dermal Diagnostics (Holdings) Limited England and Wales Corporation
Dermal Diagnostics Limited England and Wales Corporation		Trial Clinic Limited England and Wales Corporation

The Company has a limited operating history, recurring losses from operations and an accumulated deficit of $7,560,420 as of June 30, 2017.  The Company expects to continue to incur losses from operations at least until clinical trials are completed later this year and the product becomes available to be marketed.  Management has evaluated its ability to continue as a going concern for the next twelve months from the issuance of these June 30, 2017 consolidated financial statements, and considered the expected expenses to be incurred along with its available cash, and has determined that there is not substantial doubt as to its ability to continue as a going concern for at least one year subsequent to the date of issuance of these financial statements. The Company has approximately $1,284,000 of readily available cash on hand at June 30, 2017 and approximately $1.3 million will be available in December 2017, which is currently in a fixed rate deposit account.  In addition, the Company has approximately $4.5 million of cash in a fixed rate deposit account which comes due in December 2018.

Management's strategic plans include the following:

- continuing to advance commercialization of the Company's principal product, in the UK, European and other international markets;

- pursuing additional capital raising opportunities; and

- continuing to explore and execute prospective partnering or distribution opportunities.